PubMed · 2009 · 15 citations · 13 references
MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyDiabetologyCardiovascular DiseaseCardiovascular PharmacologyCardiovascular RiskDiabetes MellitusOral Antidiabetic AgentsStrokeAdverse Cardiovascular Drug EventsAntidiabetic Drug TherapyDiabetes-associated Cardiac RiskOral Antidiabetic MedicationsOral Antidiabetic TherapyType 2 Diabetes Mellitus TreatmentType 2 Diabetes Pharmacotherapy
CONTEXT.: The use of thiazolidinediones (TZDs) in patients with type-2 diabetes mellitus appears to be associated with an increased risk of myocardial infarction (MI) compared with placebo or other oral antidiabetic drug regimens. OBJECTIVE.: We conducted a study to investigate whether there was a difference in the risk of acute MI and hemorrhagic and non-hemorrhagic stroke between specific TZDs, namely rosiglitazone maleate (Avandia) and pioglitazone (Actos), and other oral antidiabetic agents in a high-risk, largely underrepresented and largely minority Medicaid population. STUDY DESIGN, SETTING, AND PATIENTS.: We analyzed patient encounter data using propensity-scoring methods and logistic regression to compare the risk of cardiovascular (CV) events in patients with type-2 diabetes in a high-risk population. MAIN OUTCOME MEASURES.: Outcomes were identified through International Classification of Disease (ICD-9) codes 410-411 for acute MI; 430-438 for stroke; and revenue (emergency department) codes 450-459 in the case of MI. RESULTS.: Using retrospective medical encounter and prescription data analyses, we found that rosiglitazone, compared with other oral antidiabetic agents, was associated with an increased rate of CV events by 20% in a high-risk cohort of diabetic patients. Neither pioglitazone nor the TZD drug class as a whole was associated with an increased CV risk. CONCLUSION.: Rosiglitazone was associated with a significant increase in CV events (MI and stroke) among high-risk patients with type-2 diabetes, whereas pioglitazone was not. We recommend further research to capture risk factors that were not observed in our encounter data.
13
Erik von Elm, Douglas G. Altman, Matthias Egger et al. · PLoS Medicine · 2007 · 21.6K citations · Full text
Public Health, Public Health Practice, Epidemiologic Methods +10
Erik von Elm, Douglas G. Altman, Matthias Egger et al. · Annals of Internal Medicine · 2007 · 17.2K citations
Public Health, Public Health Practice, Epidemiologic Methods +10